The Stent of Choice in

ACS patients

The Stent of Choice in ACS

1) The Rationale…

1) The Rationale:

Titanium-Nitride-Oxide Coating

• Absolute Lowest Thrombogenicity• Effective Restenosis Reduction

• Shortest DAP Therapy

Helicoidal Design

• Improved Trackability & Crossability

The Stent of Choice in ACS

The Stent of Choice in ACS

2) The Clinical Evidence…

Titan2 vs. The Latest DES Generation

The BASE-ACS Randomized Trial

BAS vs EES12-Month Clinical Follow-Up

TiTAN-2 XIENCE-V

SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial EuroPCR 2011

The BASE-ACS Randomized Trial

ACS Population

827 Patients

100% Patients Follow-UpSOURCE: The BASE-ACS Randomized Controlled Trial

Late Breaking Trial EuroPCR 2011

Titan2 vs. The Latest DES Generation

The BASE-ACS RCT

MACE @ 12 months

MACE: Cardiac Death, nonfatal MI or TLR

7.2%

2.6%

6.8%3.9%

TITAN-2

XIENCE-V

%

1 6 120

5

10

15

2.6%

7.2%9.6%

3.9% 6.8%9.0%

Titan-2 BAS (n=417)Xience-V EES (n=410)

Months after Index Procedure

% Pnon-inferiority = 0.001HR 0.94 (0.59-1.50)

TiTAN2 is Non-Inferior

to XIENCE V at 12 months

BAS EES0

5

10

15

20

9.6% 9.0%

The BASE-ACS RCT

MAC

E (%

)

Pnon-inferiority = 0.001

TiTAN-2 XIENCE-V

The BASE-ACS Randomized Trial

BAS vs EES18-Month Clinical Follow-Up

TiTAN-2 XIENCE-V

SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial ASIA PCR 2012

The BASE-ACS RCT

MACE: Cardiac Death, nonfatal MI or TLR

7.2%

2.6%

6.8%3.9%

TITAN-2

XIENCE-V

%

1 6 120

5

10

15

2.6%

7.2%

9.6%

3.9%6.8%

9.0%

Titan-2 BAS (n=417)Xience-V EES (n=410)

%

MACE @ 18 months

Months after Index Procedure

The BASE-ACS RCT

MACE @ 18 months

MACE: Cardiac Death, nonfatal MI or TLR

7.2%

2.6%

6.8%3.9%

Days after Index Procedure

TITAN-2

XIENCE-V

%

1 6 12 180

5

10

15

2.6%

7.2%

9.6%

3.9%6.8%

9.0%

Titan-2 BAS (n=417)Xience-V EES (n=410)

%

Months after Index Procedure

11.7%

10.8%

P = 0.74HR 0.96 (0.78-1.18)

TiTAN2 vs. XIENCE V

at 18 months

BAS EES0

5

10

15

20

10.8%11.7%

The BASE-ACS RCT

MACE (%)

P =

0.7

4

BAS EES0

5

10

15

20

2.6%

6.3%

BAS EES0

5

10

15

20

1.2%3,7%P

= 0

.01

P =

0.0

21

* Definite & Probable

AMI (%) *Thrombosis (%)

TiTAN-2 XIENCE-V TiTAN-2 XIENCE-V TiTAN-2 XIENCE-V

The BASE-ACS RCT

Titan2 vs. The Latest DES Generation

* Definite & Probable

At 12 months Titan-2 BAS demonstrates its Non-Inferiority vs.Xience-V EES in terms of MACE (9.6% vs 9.0%) in patients with ACS

At 18 months Titan2-BAS improves its MACE score vs. EES

(10.8% vs. 11.7%) due to a significantly better safety profile in terms of hard clinical endpoints:

• AMI (2.6% vs. 6.3%, p=0.01) • Thrombosis* (1.2% vs. 3.7%, p=0.021)

(with significantly less DAPT duration: 8.7 vs.10.2 months, p<0.001)

The Evidence-Based Choice for Your

ACS patients !

All cited trademarks are the property of their respective owners.This material is not intended for use in the United-States and certain other countries.Caution: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. ©2012 Hexacath or its affiliates.